Evaluating the appropriateness of digoxin level monitoring

Archives of Internal Medicine

Volumn 159, Issue 4, 1999, Pages 363-368

  Cañas, Fina ^a   Tanasijevic, Milenko J ^a   Ma'luf, Nell ^a   Bates, David W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN;

ADAPTATION; ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; FEMALE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL;

EID: 0345004145     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.4.363     Document Type: Article

References (28)

1. Fineberg HV. Clinical chemistries: the high cost of low-cost diagnostic tests. In: Altman SH, Blendon R, eds. Medical Technology: The Culprit Behind Health Care Costs. Washington, DC: US Dept of Health, Education, and Welfare; 1979:144-165.
2. Maloney TW, Rogers DE. Medical technology - a different view of the contentious debate over costs. N Engl J Med. 1979;301:1413-1419.
3. Panzer RJ, Griner PF. Inexpensive tests of limited value: sometimes you get what you pay for. J Gen Intern Med. 1987;2:365-367.
4. Aronson JK, Hardman M. ABC of monitoring drug therapy: digoxin. BMJ. 1992; 305:1149-1152.
5. Connors JE, DiPiro JT, Sisley JF. Use of serum drug concentrations in surgical patients. Am J Surg. 1988;156:68-76.
6. Fleg JL, Hinton PC, Lakatta EG, et al. Physician utilization of laboratory procedures to monitor outpatients with congestive heart failure. Arch Intern Med. 1989; 149:393-396.
7. Dobbs RJ, Nicholson PW, Denham MJ, Dobbs SM, O'Neill CJ. Therapeutic drug monitoring of digoxin: help or hindrance? Eur J Clin Pharmacol. 1986;31:491-495.
8. Wing D, Duff HJ. Impact of a therapeutic drug monitoring program for digoxin. Arch Intern Med. 1987;14:1405-1408.
9. Howanitz PJ, Steindel SJ. Digoxin therapeutic drug monitoring practices: a College of American Pathoiogists Q-Probes study of 666 institutions and 18 679 toxic levels. Arch Pathol Lab Med. 1993;117:684-690.
10. Bernard DW, Bowman RL, Grimm FA, Wolf BA, Simson MB, Shaw LM. Night-time dosing assures postdistribution sampling for therapeutic drug monitoring of digoxin. Clin Chem. 1996;42:45-49.
11. Clague HW, Twum-Barima Y, Carruthers SG. An audit ot requests for therapeutic drug monitoring of digoxin: problems and pitfalls. Ther Drug Monit. 1983;5: 249-254.
12. D'Angio RG, Stevenson JG, Lively BT, Morgan JE. Therapeutic drug monitoring: improved performance through educational intervention. Ther Drug Monit. 1990; 12:173-178.
13. Matzuk MM, Shlomchik M, Shaw LM. Making digoxin therapeutic drug monitoring more effective. Ther Drug Monit. 1991;13:215-219.
14. Michalko KJ, Blain L. An evaluation of a clinical pharmacokinetic service for serum digoxin levels. Ther Drug Monit. 1987;9:311-319.
15. Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, Pa: WB Saunders Co; 1997:480-484.
16. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW. Goodman & Gilman's The Pharmacologic Basis of Therapeutics. New York, NY: McGraw-Hill Book Co; 1996:814.
17. McDonald CJ, Overhage JM. Guidelines you can follow and trust: an ideal and an example. JAMA. 1994;271:872-873.
18. Stone JA, Soldin SJ. Update on digoxin. Clin Chem. 1989;35:1326-1331.
19. Feinstein AR. Clinical Epidemiology: The Architecture of Clinical Research. Philadelphia, Pa: WB Saunders Co; 1985:186.
20. Rosenthal R, Hosnow RL. Essentials of Behavioral Research: Methods and Data Analysis. New York, NY: McGraw-Hill Book Co; 1991:513.
21. Fleiss JL. Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons Inc; 1981.
22. SAS[computer program]. Release version 6.12. Cary, NC: SAS Institute Inc; 1997.
23. Kumana CR, Chan YM, Kou M. Audit exposes flawed blood sampling for "digoxin levels." Ther Drug Monit. 1992;14:155-159.
24. Copeland RJ, Thorpe H, Kay EA. Inappropriate digoxin monitoring. J Clin Pharm Ther. 1992;17:173-174.
25. Schoenenberger RA, Tanasijevic MJ, Jha A, Bates DW. Appropriateness of antiepileptic drug level monitoring. JAMA. 1995;274:1622-1626.
26. Bates DW, Kuperman GJ, Rittenberg E, et al. Reminders for redundant tests: results of a randomized controlled trial. Proc Ann Symp Comput Appl Med Care. 1995;19:935-935.
27. Fraser GL, Wennberg DE, Dickens JD Jr, Lambrew CT. Changing physician behavior in ordering digoxin assays. Ann Pharmacother. 1996;30:449-454.
28. Rylance GW, Moreland TA. Drug level monitoring in pediatric practice. Arch Dis Child. 1980;55:89-98.